专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100298348A1 Method of Decreasing Ubiquitylated Protein Levels 审中-公开
标题翻译：降低泛素化蛋白质水平的方法
公开(公告)号：US20100298348A1
公开(公告)日：2010-11-25
申请号：US12777586
申请日：2010-05-11
申请人： Kim Nicholas Green , Eckard Weber , Tilman Oltersdorf , Sharon Rogers , Frank LaFerla
发明人： Kim Nicholas Green , Eckard Weber , Tilman Oltersdorf , Sharon Rogers , Frank LaFerla
IPC分类号： A61K31/519 , A61K31/438 , A61K31/437 , A61K31/429 , A61K31/4166 , A61P9/00 , A61P43/00 , A61P25/28 , A61P29/00 , A61P25/16 , A61P25/00 , A61P35/00 , A61P19/08 , A61P3/10 , A61P27/12 , A61P27/00 , C12Q1/02
CPC分类号： A61K31/437 , A61K31/4188 , A61K31/429 , A61K31/4745
摘要： The present invention provides a method of decreasing the level of ubiquitylated protein in a subject, the method comprising administering a heterocyclic compound disclosed herein or a pharmaceutically acceptable salt, hydrate or prodrug thereof to a subject in need thereof.
摘要翻译：本发明提供降低受试者中泛素化蛋白质水平的方法，该方法包括向有需要的受试者施用本文公开的杂环化合物或其药学上可接受的盐，水合物或前药。

2. 发明申请

US20100168135A1 Method of Inducing Cleavage of Amyloid Precursor Protein to Form a Novel Fragment 审中-公开
标题翻译：诱导淀粉样前体蛋白切割形成新片段的方法
公开(公告)号：US20100168135A1
公开(公告)日：2010-07-01
申请号：US12638219
申请日：2009-12-15
申请人： Kim Nicholas Green , Tilman Oltersdorf , Eckard Weber
发明人： Kim Nicholas Green , Tilman Oltersdorf , Eckard Weber
IPC分类号： A61K31/437 , A61K31/429 , A61K31/519 , A61K31/4745 , C07K2/00 , C12Q1/02
CPC分类号： A61K31/429 , A61K31/437 , A61K31/4745 , A61K31/519 , G01N33/5058
摘要： The present invention provides a method of inducing cleavage of amyloid precursor protein to produce an approximately 17 kilodalton carboxy-terminal fragment of amyloid precursor protein in a subject, the method comprising administering a heterocyclic compound or a pharmaceutically acceptable salt, hydrate or prodrug thereof to a subject in need thereof, wherein the approximately 17 kilodalton fragment includes the carboxyterminal amino acid sequence of amyloid precursor protein and amyloid-beta amino acid sequence. Also provided is a screening method for identifying compounds induce cleavage of amyloid precursor protein to produce the approximately 17 kilodalton carboxy-terminal fragment of amyloid precursor protein.
摘要翻译：本发明提供诱导淀粉样蛋白前体蛋白切割以在受试者中产生淀粉样蛋白前体蛋白的约17千道尔顿羧基末端片段的方法，所述方法包括给予杂环化合物或其药学上可接受的盐，水合物或前体药物至其中约17千道尔顿片段包括淀粉样蛋白前体蛋白和淀粉样蛋白-β氨基酸序列的羧基末端氨基酸序列。还提供了用于鉴定化合物的筛选方法，诱导淀粉样蛋白前体蛋白的切割以产生淀粉样蛋白前体蛋白的约17千道尔顿羧基末端片段。

3. 发明申请

US20100267763A1 Method of Decreasing Pro-ADAM10 Secretase and/or Beta Secretase Levels 审中-公开
标题翻译：减少Pro-ADAM10分泌酶和/或β-分泌酶水平的方法
公开(公告)号：US20100267763A1
公开(公告)日：2010-10-21
申请号：US12760021
申请日：2010-04-14
申请人： Kim Nicholas GREEN , Eckard Weber
发明人： Kim Nicholas GREEN , Eckard Weber
IPC分类号： A61K31/437 , A61P25/28 , A61P35/00 , A61P11/00
CPC分类号： A61K31/437 , G01N33/5023
摘要： The present invention provides a method of decreasing the level of pro-ADAM10 and/or BACE protein in a subject, the method comprising administering a heterocyclic compound or a pharmaceutically acceptable salt, hydrate or prodrug thereof to a subject in need thereof.
摘要翻译：本发明提供了降低受试者中亲ADAM10和/或BACE蛋白的水平的方法，该方法包括向有需要的受试者施用杂环化合物或其药学上可接受的盐，水合物或前药。

4. 发明授权

US08318788B2 Layered pharmaceutical formulations 有权
公开(公告)号：US08318788B2
公开(公告)日：2012-11-27
申请号：US13330395
申请日：2011-12-19
申请人： Anthony McKinney , Gary Tollefson , Eckard Weber , Rick Soltero
发明人： Anthony McKinney , Gary Tollefson , Eckard Weber , Rick Soltero
IPC分类号： A61K9/00 , A61K31/485 , A61K31/423 , A61P3/04
CPC分类号： A61K9/209 , A61K9/0002 , A61K9/2018 , A61K9/2054 , A61K31/137 , A61K31/138 , A61K31/155 , A61K31/35 , A61K31/357 , A61K31/42 , A61K31/423 , A61K31/485 , A61K31/551 , A61K31/5513 , A61K45/06 , A61K47/26 , A61K2300/00
摘要： In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.

5. 发明授权

US08088786B2 Layered pharmaceutical formulations 有权
标题翻译：分层药物制剂
公开(公告)号：US08088786B2
公开(公告)日：2012-01-03
申请号：US11937421
申请日：2007-11-08
申请人： Anthony McKinney , Gary Tollefson , Eckard Weber , Rick Soltero
发明人： Anthony McKinney , Gary Tollefson , Eckard Weber , Rick Soltero
IPC分类号： A01N43/42 , A61K31/44
CPC分类号： A61K9/209 , A61K9/0002 , A61K9/2018 , A61K9/2054 , A61K31/137 , A61K31/138 , A61K31/155 , A61K31/35 , A61K31/357 , A61K31/42 , A61K31/423 , A61K31/485 , A61K31/551 , A61K31/5513 , A61K45/06 , A61K47/26 , A61K2300/00
摘要： In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.
摘要翻译：在一个实施方案中，分层药物制剂包含两个或更多个药物层和设置在两个或更多个药物层中的至少两个之间的中间层，所述中间层被配置为在体内溶解，从而使两个或更多个药物层基本上保持完好。在一个实施方案中，至少一个药物层中的活性药物成分选自安非他酮，唑尼沙胺，纳曲酮，托吡酯，芬特明，二甲双胍，奥氮平和氟西汀。

6. 发明申请

US20110059170A1 METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS 有权
标题翻译：管理重量损失药物的方法
公开(公告)号：US20110059170A1
公开(公告)日：2011-03-10
申请号：US12838364
申请日：2010-07-16
申请人： Anthony McKinney , Gary Tollefson , Eckard Weber , Rick Soltero
发明人： Anthony McKinney , Gary Tollefson , Eckard Weber , Rick Soltero
IPC分类号： A61K9/20 , A61K31/415 , A61K31/137 , A61K31/439 , A61K31/35 , A61K31/551 , A61P3/04
CPC分类号： A61K9/209 , A61J1/035 , A61J7/04 , A61J7/0454 , A61K31/135 , A61K31/137 , A61K31/138 , A61K31/35 , A61K31/42 , A61K31/423 , A61K31/485 , A61K31/551 , A61K31/5513 , A61K31/7048 , A61K45/06 , B65D75/36 , A61K2300/00
摘要： Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.
摘要翻译：用于使用包括具有第一药物和第二药物的第一单位剂量的单位剂量包装的药物的给药方法和系统，具有第一药物和第二药物的第二单位剂量，其中第二单位剂量包括不同的第二药物的量比第一单位剂量和单位剂量包装被配置为保持第一单位剂量和第二单位剂量。在优选的实施方案中，所述方法和系统用于施用减肥药物。

7. 发明授权

US06872390B2 Local anesthetic methods and kits 有权
标题翻译：局部麻醉方法和试剂盒
公开(公告)号：US06872390B2
公开(公告)日：2005-03-29
申请号：US10155020
申请日：2002-05-28
申请人： Eckard Weber , Howard I. Katz
发明人： Eckard Weber , Howard I. Katz
IPC分类号： A61K45/06 , A61K20060101 , A61K31/135 , A61K31/137 , A61K31/165 , A61K31/166 , A61K31/167 , A61K31/24 , A61K31/415 , A61K31/417 , A61K31/44 , A61K31/445 , A61K31/505 , A61K38/46 , A61P23/02 , A61P43/00 , A01N25/00
CPC分类号： A61K31/135 , A61K31/165 , A61K31/24 , A61K31/415 , A61K31/44 , A61K31/445 , A61K31/505 , Y10S435/81 , Y10S514/816 , Y10S514/818
摘要： Methods of reversing local anesthesia are disclosed. The methods comprise administering a local anesthetic and alpha adrenergic receptor agonist to induce local anesthesia followed by reversing anesthesia with a low dose of an alpha adrenergic receptor antagonist. Also disclosed are kits comprising a local anesthetic, an alpha adrenergic receptor agonist and a low dose of an alpha adrenergic receptor antagonist.
摘要翻译：公开了逆转局部麻醉的方法。所述方法包括施用局部麻醉剂和α肾上腺素能受体激动剂以诱导局部麻醉，然后用低剂量的α肾上腺素能受体拮抗剂逆转麻醉。还公开了包含局部麻醉剂，α肾上腺素能受体激动剂和低剂量α肾上腺素能受体拮抗剂的试剂盒。

8. 发明授权

US06458843B1 Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof 有权
标题翻译：碳环和杂环取代的缩氨基脲和缩氨基硫脲和其用途
公开(公告)号：US06458843B1
公开(公告)日：2002-10-01
申请号：US09421403
申请日：1999-10-21
申请人： Yan Wang , Sui Xiong Cai , Nancy C. Lan , John F. W. Keana , Victor I. Ilyin , Eckard Weber
发明人： Yan Wang , Sui Xiong Cai , Nancy C. Lan , John F. W. Keana , Victor I. Ilyin , Eckard Weber
IPC分类号： A61K3117
CPC分类号： C07D213/643 , A61K31/17 , A61K31/175 , A61K31/44 , A61K31/445 , A61K31/47 , A61K31/505 , C07C281/12 , C07C281/14 , C07C2601/14 , C07D209/14 , C07D211/46 , C07D213/68 , C07D215/12 , C07D307/91 , C07D309/12 , C07D317/50 , C07D317/58 , C07D317/62 , C07D317/64 , C07D319/18
摘要： This invention is related to carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones represented by Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein: Y is oxygen or sulfur; R1, R21, R22 and R23 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl; or R22 and R23, together with the N, form a heterocycle; A1 and A2 are independently aryl, heteroaryl, saturated or partially unsaturated carbocycle or saturated or partially unsaturated heterocycle, any of which is optionally substituted; X is one or O, S, NR24, CR25R26, C(O), NR24C(O), C(O)NR24, SO, SO2 or a covalent bond; where R24, R25 and R26 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl. The invention also is directed to the use of carbocycle and heterocycle substituted semicarbazones and thiosemicarbazones for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), for the treatment and prevention of otoneurotoxicity and eye diseases involving glutamate toxicity and for the treatment, prevention or amelioration of pain, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy and urinary incontinence.
摘要翻译：本发明涉及由式I表示的碳环和杂环取代的缩氨基脲和缩氨基硫脲或其药学上可接受的盐或前药，其中：Y是氧或硫; R1，R21，R22和R23独立地是氢，烷基，环烷基，烯基，炔基，卤代烷基，芳基，氨基烷基，羟基烷基，烷氧基烷基或羧基烷基; 或R 22和R 23与N一起形成杂环; A1和A2独立地是芳基，杂芳基，饱和或部分不饱和的碳环或饱和或部分不饱和的杂环，其中任何一个任选被取代; X是1或O，S，NR 24，CR 25 R 26，C（O），NR 24 C（O），C（O）NR 24，SO，SO 2或共价键; 其中R 24，R 25和R 26独立地是氢，烷基，环烷基，烯基，炔基，卤代烷基，芳基，氨基烷基，羟基烷基，烷氧基烷基或羧基烷基。本发明还涉及使用碳环和杂环取代的缩氨基脲和缩氨基硫脲来治疗全身和局部缺血后的神经元损伤，用于治疗或预防神经变性疾病如肌萎缩性侧索硬化（ALS），用于治疗和预防涉及谷氨酸毒性和治疗，预防或改善疼痛，作为抗惊厥药，以及作为局部麻醉剂，作为抗心律失常药物和用于治疗或预防糖尿病性神经病和尿失禁的抗疟药抑制剂。

9. 发明授权

US6124317A 2-substituted piperidine analogs and their use as subtype-selective NMDA receptor antagonists 失效
标题翻译： 2-取代的哌啶类似物及其作为亚型选择性NMDA受体拮抗剂的用途
公开(公告)号：US6124317A
公开(公告)日：2000-09-26
申请号：US91593
申请日：1998-11-18
申请人： Christopher F. Bigge , John F. W. Keana , Sui Xiong Cai , Eckard Weber , Richard Woodward , Nancy C. Lan , Anthony P. Guzikowski
发明人： Christopher F. Bigge , John F. W. Keana , Sui Xiong Cai , Eckard Weber , Richard Woodward , Nancy C. Lan , Anthony P. Guzikowski
IPC分类号： A61K31/445 , A61K31/454 , C07D211/14 , C07D401/12 , A01N43/40
CPC分类号： C07D401/12 , A61K31/445 , A61K31/454 , C07D211/14
摘要： Novel 2-substituted piperidine analogs, pharmaceutical compositions containing the same and the method of using 2-substituted piperidine analogs as selectively active antagonists of N-methyl-D-aspartatc (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, hypoglycemia, anxiety, convulsions, amioglycoside antibiotics-induced hearing loss, migraine headaches, chronic pain, glaucoma, CMV retinitis, psychosis, urinary incontinence, opioid tolerance or withdrawal, or neurodegenerative disorders, such as lathyrism, Alzheimer's Disease, Parkinsonism and Huntington's Disease are described.
摘要翻译： PCT No.PCT / US96 / 20767 Sec。 371日期：1998年11月18日 102（e）1998年11月18日日期PCT 1996年12月20日PCT公布。出版物WO97 / 23215 PCT 日期1997年7月3日新颖的2-取代的哌啶类似物，含有它们的药物组合物和使用2-取代的哌啶类似物作为N-甲基-D-天冬氨酸（NMDA）受体亚型的选择性活性拮抗剂的方法，用于治疗诸如中风脑缺血，中枢神经系统创伤，低血糖，焦虑症，惊厥，阿糖苷类抗生素诱发的听力损失，偏头痛，慢性疼痛，青光眼，CMV视网膜炎，精神病，尿失禁，阿片样物质耐受或戒断，或神经退行性疾病，阿尔茨海默病，帕金森综合征和亨廷顿氏病。

10. 发明授权

US5767162A Tri-and tetra-substituted guanidines and their use as excitatory amino acid antagonists 失效
标题翻译：三取代和四取代的胍和它们作为兴奋性氨基酸拮抗剂的用途
公开(公告)号：US5767162A
公开(公告)日：1998-06-16
申请号：US470345
申请日：1995-06-06
申请人： Eckard Weber , John F. W. Keana
发明人： Eckard Weber , John F. W. Keana
IPC分类号： A61K31/155 , C07C279/18 , C07D311/18 , A61K31/37 , A61K31/655
CPC分类号： A61K31/155 , C07C279/18 , C07D311/18
摘要： Tri- and tetra-substituted guanidines which exhibit a high binding affinity to phencyclidine (PCP) receptors and, more preferably, low affinity to the brain sigma receptors. These guanidine derivatives act as non-competitive inhibitors of glutamate induced responses of the NMDA receptor by acting as blockers for the ion channel of the NMDA receptor-ion channel complex. These compounds thus exert neuroprotective activity and are useful in the therapeutic treatment of neuronal loss in hypoxia, hypoglycemia, brain or spinal cord ischemia, and brain or spinal chord trauma as well as being useful for the treatment of epilepsy, Alzheimer's disease, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, Down's Syndrome, Korsakoff's disease and other neurodegenerative disorders.
摘要翻译：表现出对苯环利定（PCP）受体的高结合亲和力，更优选对大脑σ受体的低亲和力的三取代和四取代胍基。这些胍衍生物通过作为NMDA受体 - 离子通道复合物的离子通道的阻断剂，作为NMDA受体的谷氨酸诱导反应的非竞争性抑制剂。因此，这些化合物发挥神经保护活性，并且可用于治疗缺氧，低血糖，脑或脊髓缺血以及脑或脊髓创伤中的神经元损失，以及用于治疗癫痫，阿尔茨海默病，肌萎缩性侧索硬化症，帕金森病，亨廷顿舞蹈病，唐氏综合征，柯萨科夫病和其他神经退行性疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式